BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 34338285)

  • 1. Identification of candidate miRNA biomarkers for facioscapulohumeral muscular dystrophy using DUX4-based mouse models.
    Nunes AM; Ramirez M; Jones TI; Jones PL
    Dis Model Mech; 2021 Aug; 14(8):. PubMed ID: 34338285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transgenic mice expressing tunable levels of DUX4 develop characteristic facioscapulohumeral muscular dystrophy-like pathophysiology ranging in severity.
    Jones TI; Chew GL; Barraza-Flores P; Schreier S; Ramirez M; Wuebbles RD; Burkin DJ; Bradley RK; Jones PL
    Skelet Muscle; 2020 Apr; 10(1):8. PubMed ID: 32278354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human miRNA miR-675 inhibits DUX4 expression and may be exploited as a potential treatment for Facioscapulohumeral muscular dystrophy.
    Saad NY; Al-Kharsan M; Garwick-Coppens SE; Chermahini GA; Harper MA; Palo A; Boudreau RL; Harper SQ
    Nat Commun; 2021 Dec; 12(1):7128. PubMed ID: 34880230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Muscle eosinophilia is a hallmark of chronic disease in facioscapulohumeral muscular dystrophy.
    Nunes AM; Ramirez MM; Garcia-Collazo E; Jones TI; Jones PL
    Hum Mol Genet; 2024 May; 33(10):872-883. PubMed ID: 38340007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of DUX4 in zebrafish development recapitulates facioscapulohumeral muscular dystrophy.
    Mitsuhashi H; Mitsuhashi S; Lynn-Jones T; Kawahara G; Kunkel LM
    Hum Mol Genet; 2013 Feb; 22(3):568-77. PubMed ID: 23108159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Facioscapulohumeral muscular dystrophy family studies of DUX4 expression: evidence for disease modifiers and a quantitative model of pathogenesis.
    Jones TI; Chen JC; Rahimov F; Homma S; Arashiro P; Beermann ML; King OD; Miller JB; Kunkel LM; Emerson CP; Wagner KR; Jones PL
    Hum Mol Genet; 2012 Oct; 21(20):4419-30. PubMed ID: 22798623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinically Advanced p38 Inhibitors Suppress DUX4 Expression in Cellular and Animal Models of Facioscapulohumeral Muscular Dystrophy.
    Oliva J; Galasinski S; Richey A; Campbell AE; Meyers MJ; Modi N; Zhong JW; Tawil R; Tapscott SJ; Sverdrup FM
    J Pharmacol Exp Ther; 2019 Aug; 370(2):219-230. PubMed ID: 31189728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Muscle pathology from stochastic low level DUX4 expression in an FSHD mouse model.
    Bosnakovski D; Chan SSK; Recht OO; Hartweck LM; Gustafson CJ; Athman LL; Lowe DA; Kyba M
    Nat Commun; 2017 Sep; 8(1):550. PubMed ID: 28916757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DUX4, a candidate gene for facioscapulohumeral muscular dystrophy, causes p53-dependent myopathy in vivo.
    Wallace LM; Garwick SE; Mei W; Belayew A; Coppee F; Ladner KJ; Guttridge D; Yang J; Harper SQ
    Ann Neurol; 2011 Mar; 69(3):540-52. PubMed ID: 21446026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Targeted Approach for Evaluating DUX4-Regulated Proteins as Potential Serum Biomarkers for Facioscapulohumeral Muscular Dystrophy Using Immunoassay Proteomics.
    Campbell AE; Arjomand J; King OD; Tawil R; Jagannathan S
    J Neuromuscul Dis; 2023; 10(6):1031-1040. PubMed ID: 37899061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Epigenetic Regulators of DUX4-fl for Targeted Therapy of Facioscapulohumeral Muscular Dystrophy.
    Himeda CL; Jones TI; Virbasius CM; Zhu LJ; Green MR; Jones PL
    Mol Ther; 2018 Jul; 26(7):1797-1807. PubMed ID: 29759937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathomechanisms and biomarkers in facioscapulohumeral muscular dystrophy: roles of DUX4 and PAX7.
    Banerji CRS; Zammit PS
    EMBO Mol Med; 2021 Aug; 13(8):e13695. PubMed ID: 34151531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Muscle xenografts reproduce key molecular features of facioscapulohumeral muscular dystrophy.
    Mueller AL; O'Neill A; Jones TI; Llach A; Rojas LA; Sakellariou P; Stadler G; Wright WE; Eyerman D; Jones PL; Bloch RJ
    Exp Neurol; 2019 Oct; 320():113011. PubMed ID: 31306642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PAX7 target gene repression is a superior FSHD biomarker than DUX4 target gene activation, associating with pathological severity and identifying FSHD at the single-cell level.
    Banerji CRS; Zammit PS
    Hum Mol Genet; 2019 Jul; 28(13):2224-2236. PubMed ID: 31067297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DUX4-induced gene expression is the major molecular signature in FSHD skeletal muscle.
    Yao Z; Snider L; Balog J; Lemmers RJ; Van Der Maarel SM; Tawil R; Tapscott SJ
    Hum Mol Genet; 2014 Oct; 23(20):5342-52. PubMed ID: 24861551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of
    Duranti E; Villa C
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The evolution of DUX4 gene regulation and its implication for facioscapulohumeral muscular dystrophy.
    Jagannathan S
    Biochim Biophys Acta Mol Basis Dis; 2022 May; 1868(5):166367. PubMed ID: 35158020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morpholino-mediated Knockdown of DUX4 Toward Facioscapulohumeral Muscular Dystrophy Therapeutics.
    Chen JC; King OD; Zhang Y; Clayton NP; Spencer C; Wentworth BM; Emerson CP; Wagner KR
    Mol Ther; 2016 Aug; 24(8):1405-11. PubMed ID: 27378237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DUX4 expressing immortalized FSHD lymphoblastoid cells express genes elevated in FSHD muscle biopsies, correlating with the early stages of inflammation.
    Banerji CRS; Panamarova M; Zammit PS
    Hum Mol Genet; 2020 Aug; 29(14):2285-2299. PubMed ID: 32242220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DUX4 Transcript Knockdown with Antisense 2'-O-Methoxyethyl Gapmers for the Treatment of Facioscapulohumeral Muscular Dystrophy.
    Lim KRQ; Bittel A; Maruyama R; Echigoya Y; Nguyen Q; Huang Y; Dzierlega K; Zhang A; Chen YW; Yokota T
    Mol Ther; 2021 Feb; 29(2):848-858. PubMed ID: 33068777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.